DOCSLIB.ORG

B Cell Elimination in MS, Predictors of Good Response and Changes in CSF

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
B Cell Elimination in MS, Predictors of Good Response and Changes in CSF B cell elimination in MS, Predictors of good Response and Changes in CSF Anne H. Cross Washington University School of Medicine St. Louis, Missouri Disclosures Anne Cross has served as a consultant for: Abbvie, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Teva And has research grants from Biogen and Genentech Outline 1. Biomarkers predicting response to anti-CD20 monoclonal antibodies 2. Animal models 3. B cell-targeted therapy that failed in MS 4. Is there a more focused B cell target? Reduction in ARR vs IFNB1a in RRMS: OPERA I and II 12 and 24 week Confirmed disability worsening reduced 40% in OPERA I & II >90% reduction in Gad+ lesions in RRMS: OPERA I and II Surface markers during B cells Development Immature B cell Naïve Memory Stem Cell mature B B cell Plasmablast Plasma cell CD20 CD19 CD138 CD27 (memory) Major histocompatibility complex-Class II Based on Mei HE, et al. Rationale of anti-CD19 immunotherapy: an option to target auto-reactive plasma cells in autoimmunity Arthritis Research & Therapy 2012, 14(Suppl 5):S1. No agent that specifically targets B-cells has yet been approved for clinical use in MS • Two monoclonal antibodies (mAbs) that eliminate B cells (ocrelizumab, ofatumumab) by targeting CD20 are in MS pipeline. • It is expected that one or more agents will receive agency approval for MS within the coming 1-2 years Using animal studies to unravel the roles of B cells How might B cells work with T cells to induce CNS demyelination? Murine experimental autoimmune encephalomyelitis model Animal model studies B cells essential when long protein (not peptide) used as antigen Lyons & Cross, 1999; Weber, Zamvil 2010 Goverman Lab Th1 antigen-specific T cells reactivated in CNS by B cells • Most MHC II+ cells in naïve mouse brain are B cells (CD19+) • Passive transfer MOG-specific T cells normal vs. B cell deficient mice. Similar numbers of T cells in CNS at day 4 (pre-clinical), but by day 7 the encephalitogenic T cells had ↑d in numbers in normal mice and ↓d in B-cell deficient mice. • Not due to ↑d in situ proliferation, • Increased T cells were due to ↑d recruitment from the periphery Pierson ER, Stromnes IM, Goverman JM. B cells promote induction of EAE by facilitating reactivation of T cells in the central nervous system. J. Immunol 2014 Greg Wu Lab: MHCII expressed only by B cells Resistant to passive EAE 4.0 WT WT CD19Cre- 3.0 BMHCII 2.0 Clinical Score Score Clinical 1.0 0.0 0 10 20 30 Day post-transfer Archambault, et al. J Immunol. 2013; 191:545-550. B cells abundantly express BCR targeting MOG susceptible to passive EAE BMHCII x BCRMOG 4.0 WT WT CD19Cre-BMHCII 3.0 BMHCII MOG-IgH/CreBMHCII x BCR + MO MOG BCR Mouse 2.0 Clinical Score Score Clinical 1.0 0.0 0 10 20 30 Day post-transfer Parker Harp et al, J Immunol. 2015;194:5077-84. Conclusions •Animal studies: antigen-specific B cells are key for activation of autoimmune T cells in response to a protein antigen •B cells in the CNS recruit T cells into CNS, as well as reactivate them Evidence-based treatment selection •14 MS disease-modifying treatment options now FDA approved. •Choice of treatment remains largely empirical. •Methods are needed to predict who will respond to specific treatments: How do we choose the best patients for anti-CD20 therapy? Objective: Determine characteristics of patients who responded best to anti-CD20 B cell depletion •Phase II study of the B cell depleting anti-CD20 mAb, rituximab, as an add-on agent in 30 relapsing MS patients who were sub-optimally treated with an injectable. • Some patients responded with “no evident disease activity”. •Clinical data along with MRI metrics were collected as part of this study. Additionally, 24 of the 30 patients had CSF banked pre- and post-treatment. •We sought predictors of optimal response to rituximab, a chimeric anti-CD20 mAb Phase II Trial of Rituximab as “add-on” to BIFN or GA • Dosing was oncology dosing – 375mg/m2 x 4, 1 week apart. • 30 patients enrolled in study, 24 of whom had CSF collected pre and post treatment. Naismith et al, Neurology, 2010 Phase II Trial of Rituximab: 88% reduction in Gad+ lesions Pre- mean =2.81 Post – mean = 0.33 Pre 1. Cross AH, et al.. J. Neuroimmunol. 2006; 180:63-70. 2. Naismith RT et al. Neurology 2010; 74: 1860-1867 Definitions: NEDA vs non-NEDA • Patients were categorized into: • Ideal responders (NEDA) had no Gad-enhancing lesions, no relapses and stable or improved clinical exams after treatment. N=9 • Non-responders had a relapse or clinical deterioration, or no reduction in number of enhancing-lesions after B cell depletion. N=21 Clinical & statistical methods • Expanded Disability Status Scale (EDSS) determined by single examiner (AHC) • MSFC done by coordinator blinded to assay • MRI results- blinded to order in time and to assay results Demographics of NEDA responders and non-NEDA subjects Alvarez E, et al. MSJ-ETC ,2016. Baseline Predictors of NEDA: Clinical and Imaging Optimal responders had faster (A) 9-hole peg test times (dominant and non- dominant), (B) 25 FTW times, (C) lower Expanded Disability Status Scale, (D) higher numbers of contrast enhancing lesions Alvarez E, et al. MSJ-ETC ,2016. Blood and Spinal Fluid Assays • CSF Levels of CXCL13, CCL19, B cell activating factor (BAFF), MBP, Neurofilament Light and Heavy chain, antibodies to recombinant hMOG • ELISAs performed blinded to response status • Index values for CXCL13, BAFF and IgG index: Index= (CSF level/serum level) ÷ (CSF albumin/serum albumin) Baseline CSF IgG Index is predictive of response Median baseline CSF IgG Index 1.17 vs 0.67, p=0.04. 60% of the ideal responders had Index>1.0, vs only 20% of those in the non-ideal group Results: Baseline Predictors Optimal responders had higher Intrathecally synthesized CXCL13 calculated by “CXCL13 Index” (p=0.028). However, much overlap. ROC curve : 0.8. Combined CSF IgG Index and CXCL13 Index ROC Curve Sensitivity as a function of specificity – 1.0 is ideal predictor BAFF Index, NF levels & MBP levels did not predict NEDA BAFF/Blys (B cell activating factor / B-Lymphocyte Stimulator) enhances B-cell maturation, function and survival. BAFF upregulated in MS patient brains; astrocytes are a source as well as T cells & dendritic cells. B cells express the receptors (TACI and BCMA) for BAFF. CSF Neurofilament levels and CSF MBP levels were not predictive of response to rituximab either Limitations • Low number of patients • Exploratory in nature • Retrospective • Clinical assessments not blinded Biomarker responses supported NEDA: MBP, NFL and NFH levels were stable or ↓ in all NEDA responders CSF (A) myelin basic protein, (B) neurofilament light, (C) neurofilament heavy, and (D) CXCL13 levels pre- and post-rituximab. Optimal responders meeting NEDA are in solid lines; non-NEDA responders in dotted lines. CSF from Rituximab Ph2 study: B cells greatly reduced as well as T cells reduced CSF T Cells Pre- vs Post-Rituximab CSF B Cells Pre- vs Post-Rituximab 5000 300 4000 p=0.0001 Wilcoxon matched pairs test p=0.0001, 250 3000 Wilcoxon matched pairs 2000 200 test 1800 40 1200 20 600 #CD3+ cells/ml CSF # CD19+ cells/ml CSF 0 0 Week 0 Week 24-30 Pre- vs Post-Rituximab Week 0 Week 24 Rituximab Ph2 study: Decline in CSF T cells correlated with decline in CSF CXCL13 (r=0.45, p=0.03, Spearman rank correlation, n=23 pairs) R= 0.45 P = 0.03 0.25 0.00 -0.25 -0.50 -0.75 CXCL13 % change % CXCL13 -1.00 0 5 5 0 .0 .7 .2 .5 -1 -0 -0.50 -0.25 0.00 0 0 0.75 1.00 CD3+ cells/ml % change Conclusions •Patients who achieve NEDA in response to B cell depletion: Higher IgG indices and higher CXCL13 indices •Contrast enhancing lesions and better baseline neurologic status increase chances of NEDA. • Anti-CD20 rituximab treatment reduced CSF biomarkers of tissue destruction (MBP, neurofilament) and inflammation, especially in the ideal responders. •CXCL13 greatly decreased by the depletion of B cells About CXCL13 • CXCL13 is an essential chemokine in establishing and maintaining germinal centers in lymphoid tissues. • Receptor is CXCR5 • Chemotactic for B cells, activated T cells, some DCs • CXCL13 is critical to ectopic lymphoid follicles, found in progressive forms of MS, assoc’d with worse outcomes B220 CD3 CXCL13 B CELLS T CELLS CXCL13 and MS • CSF CXCL13 Levels higher in MS patients than controls Khademi et al, Mult Scler 2011 Higher CXCL13 not MS-specific: ↑ in inflammatory CNS diseases • MS, NMO and other inflammatory CNS control patients have higher CXCL13 levels in CSF than non-inflammatory controls. • CSF CXCL13 had moderate correlation with baseline EDSS, also correlated in our study with WBC #, oligoclonal band #, NFH and IgG Index Alvarez E et al. Mult Scler. 2013;19:1204-8. CSF CXCL13 correlates with total WBCs and B cell numbers in CSF in RRMS patients Sellebjerg et al, Neurology 2009 CSF CXCL13 levels associated with MS activity Khademi et al, 2010 Do Approved Disease Modifying therapies affect B cells? We reviewed published research articles and pivotal clinical trial data Longbrake and Cross JAMA Neurol. 2016 Most Approved Disease Modifying therapies affect B cells Drug Mechanism of Action related to B-cells Effect on Circulating B-cells Increased BAFF Increased total numbers Decreased expression of costimulatory molecules Relave ↑ transional Interferon-Beta Impaired antigen presentation Relave ↓ class-switched memory Inhibits pro-inflammatory cytokines (e.g. IL-1β, IL-23) Increased anti-inflammatory cytokines (IL-10) Decreased BAFF Decreased total numbers Glatiramer Impaired antigen presentation Relave ↑ naïve acetate ↓ pro-inflammatory cytokines (e.g.
Load more

Recommended publications
  • CXCL13/CXCR5 Interaction Facilitates VCAM-1-Dependent Migration in Human Osteosarcoma
    International Journal of Molecular Sciences Article CXCL13/CXCR5 Interaction Facilitates VCAM-1-Dependent Migration in Human Osteosarcoma 1, 2,3,4, 5 6 7 Ju-Fang Liu y, Chiang-Wen Lee y, Chih-Yang Lin , Chia-Chia Chao , Tsung-Ming Chang , Chien-Kuo Han 8, Yuan-Li Huang 8, Yi-Chin Fong 9,10,* and Chih-Hsin Tang 8,11,12,* 1 School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei City 11031, Taiwan; [email protected] 2 Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Puzi City, Chiayi County 61363, Taiwan; [email protected] 3 Department of Nursing, Division of Basic Medical Sciences, and Chronic Diseases and Health Promotion Research Center, Chang Gung University of Science and Technology, Puzi City, Chiayi County 61363, Taiwan 4 Research Center for Industry of Human Ecology and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Guishan Dist., Taoyuan City 33303, Taiwan 5 School of Medicine, China Medical University, Taichung 40402, Taiwan; [email protected] 6 Department of Respiratory Therapy, Fu Jen Catholic University, New Taipei City 24205, Taiwan; [email protected] 7 School of Medicine, Institute of Physiology, National Yang-Ming University, Taipei City 11221, Taiwan; [email protected] 8 Department of Biotechnology, College of Health Science, Asia University, Taichung 40402, Taiwan; [email protected] (C.-K.H.); [email protected] (Y.-L.H.) 9 Department of Sports Medicine, College of Health Care, China Medical University, Taichung 40402, Taiwan 10 Department of Orthopedic Surgery, China Medical University Beigang Hospital, Yunlin 65152, Taiwan 11 Department of Pharmacology, School of Medicine, China Medical University, Taichung 40402, Taiwan 12 Chinese Medicine Research Center, China Medical University, Taichung 40402, Taiwan * Correspondence: [email protected] (Y.-C.F.); [email protected] (C.-H.T.); Tel.: +886-4-2205-2121-7726 (C.-H.T.); Fax: +886-4-2233-3641 (C.-H.T.) These authors contributed equally to this work.
    [Show full text]
  • The Unexpected Role of Lymphotoxin Β Receptor Signaling
    Oncogene (2010) 29, 5006–5018 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The unexpected role of lymphotoxin b receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development MJ Wolf1, GM Seleznik1, N Zeller1,3 and M Heikenwalder1,2 1Department of Pathology, Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland and 2Institute of Virology, Technische Universita¨tMu¨nchen/Helmholtz Zentrum Mu¨nchen, Munich, Germany The cytokines lymphotoxin (LT) a, b and their receptor genesis. Consequently, the inflammatory microenviron- (LTbR) belong to the tumor necrosis factor (TNF) super- ment was added as the seventh hallmark of cancer family, whose founder—TNFa—was initially discovered (Hanahan and Weinberg, 2000; Colotta et al., 2009). due to its tumor necrotizing activity. LTbR signaling This was ultimately the result of more than 100 years of serves pleiotropic functions including the control of research—indeed—the first observation that tumors lymphoid organ development, support of efficient immune often arise at sites of inflammation was initially reported responses against pathogens due to maintenance of intact in the nineteenth century by Virchow (Balkwill and lymphoid structures, induction of tertiary lymphoid organs, Mantovani, 2001). Today, understanding the underlying liver regeneration or control of lipid homeostasis. Signal- mechanisms of why immune cells can be pro- or anti- ing through LTbR comprises the noncanonical/canonical carcinogenic in different types of tumors and which nuclear factor-jB (NF-jB) pathways thus inducing cellular and molecular inflammatory mediators (for chemokine, cytokine or adhesion molecule expression, cell example, macrophages, lymphocytes, chemokines or proliferation and cell survival.
    [Show full text]
  • Defining Natural Antibodies
    PERSPECTIVE published: 26 July 2017 doi: 10.3389/fimmu.2017.00872 Defining Natural Antibodies Nichol E. Holodick1*, Nely Rodríguez-Zhurbenko2 and Ana María Hernández2* 1 Department of Biomedical Sciences, Center for Immunobiology, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States, 2 Natural Antibodies Group, Tumor Immunology Division, Center of Molecular Immunology, Havana, Cuba The traditional definition of natural antibodies (NAbs) states that these antibodies are present prior to the body encountering cognate antigen, providing a first line of defense against infection thereby, allowing time for a specific antibody response to be mounted. The literature has a seemingly common definition of NAbs; however, as our knowledge of antibodies and B cells is refined, re-evaluation of the common definition of NAbs may be required. Defining NAbs becomes important as the function of NAb production is used to define B cell subsets (1) and as these important molecules are shown to play numerous roles in the immune system (Figure 1). Herein, we aim to briefly summarize our current knowledge of NAbs in the context of initiating a discussion within the field of how such an important and multifaceted group of molecules should be defined. Edited by: Keywords: natural antibody, antibodies, natural antibody repertoire, B-1 cells, B cell subsets, B cells Harry W. Schroeder, University of Alabama at Birmingham, United States NATURAL ANTIBODY (NAb) PRODUCING CELLS Reviewed by: Andre M. Vale, Both murine and human NAbs have been discussed in detail since the late 1960s (2, 3); however, Federal University of Rio cells producing NAbs were not identified until 1983 in the murine system (4, 5).
    [Show full text]
  • The Role of CXCR5 and Its Ligand CXCL13 in The
    European Journal of Endocrinology (2004) 150 225–234 ISSN 0804-4643 EXPERIMENTAL STUDY The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases G Aust, D Sittig, L Becherer1, U Anderegg2, A Schu¨tz3, P Lamesch1 and E Schmu¨cking Institute of Anatomy, 1Department of Surgery, 2Department of Dermatology and 3 Institute of Pathology, University of Leipzig, Leipzig, Germany (Correspondence should be addressed to G Aust, University of Leipzig, Institute of Anatomy, Ph-Rosenthal-Strasse 55, Leipzig, 04103, Germany; Email: [email protected]) Abstract Objective: Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) are characterized by lymphocytic infiltrates partly resembling secondary lymphoid follicles in the thyroid. CXCR5 and its ligand CXCL13 regulate compartmentalization of B- and T-cells in secondary lymphoid organs. The aim of the study was to elucidate the role of this chemokine receptor–ligand pair in thyroid autoimmunity. Methods: Peripheral blood and thyroid-derived lymphocyte subpopulations were examined by flow cyto- metry for CXCR5. CXCR5 and CXCL13 cDNA were quantified in thyroid tissues by real-time RT-PCR. Results: We found no differences between the percentages of peripheral blood CXCR5þ T- and B-cells in GD patients (n ¼ 10) and healthy controls (n ¼ 10). In GD patients, the number of memory CD4þ cells expressing CXCR5 which are functionally characterized as follicular B helper T-cells is higher in thyroid- derived (18^3%) compared with peripheral blood T-lymphocytes (8^2%). The highest CXCL13 mRNA levels were found in HT (n ¼ 2, 86.1^1.2 zmol (10221 mol) cDNA/PCR) followed by GD tissues (n ¼ 16, 9.6^3.5).
    [Show full text]
  • Etters to the Ditor
    LETTERS TO THE EDITOR even in patients with modest or no changes in BM tumor CXCL13 levels are elevated in patients with infiltration, suggesting a contributing mechanism in addi- Waldenström macroglobulinemia, and are tion to tumor debulking.6 Anemia in some WM patients predictive of major response to ibrutinib may be related to elevated hepcidin levels produced by LPL cells.7 However, the effect of ibrutinib on hepcidin Waldenström macroglobulinemia (WM) is character- remains unknown. Serum cytokines are important in ized by bone marrow (BM) infiltration of monoclonal WM biology and can be produced either by the malig- Immunoglobulin M (IgM) secreting lymphoplasmacytic nant cells, the surrounding microenvironmental cells, as lymphoma (LPL), and typically presents with anemia. well as by cells of the immune system.8 The anti-tumor MYD88 and CXCR4 activating somatic mutations effect of ibrutinib may impact all of these compartments, (CXCR4MUT) are common in WM, and found in 90-95% 1–3 including cytokines that may support growth and sur- and 35-40% of WM patients, respectively. Activating vival of tumor cells, and contribute to morbidity in WM, mutations in MYD88 support tumor growth via nuclear 9,10 factor kappa-light-chain enhancer-of-activated B-cells including anemia. As such, we aimed to characterize the serum cytokine profile in WM patients based on (NF-κB), which is triggered by Interleukin (IL)-1 receptor- associated kinases (IRAK4/IRAK1) and Bruton’s tyrosine MYD88 and CXCR4 mutation status, and to characterize kinase (BTK).4 A distinct transcriptome signature based serum cytokine and hepcidin changes in response to ibru- on both MYD88 and CXCR4 mutation status has been tinib therapy.
    [Show full text]
  • And B Cell-Associated Cytokine And
    Gyllemark et al. Journal of Neuroinflammation (2017) 14:27 DOI 10.1186/s12974-017-0789-6 RESEARCH Open Access Intrathecal Th17- and B cell-associated cytokine and chemokine responses in relation to clinical outcome in Lyme neuroborreliosis: a large retrospective study Paula Gyllemark1* , Pia Forsberg2, Jan Ernerudh3 and Anna J. Henningsson4 Abstract Background: B cell immunity, including the chemokine CXCL13, has an established role in Lyme neuroborreliosis, and also, T helper (Th) 17 immunity, including IL-17A, has recently been implicated. Methods: We analysed a set of cytokines and chemokines associated with B cell and Th17 immunity in cerebrospinal fluid and serum from clinically well-characterized patients with definite Lyme neuroborreliosis (group 1, n = 49), defined by both cerebrospinal fluid pleocytosis and Borrelia-specific antibodies in cerebrospinal fluid and from two groups with possible Lyme neuroborreliosis, showing either pleocytosis (group 2, n = 14) or Borrelia-specific antibodies in cerebrospinal fluid (group 3, n = 14). A non-Lyme neuroborreliosis reference group consisted of 88 patients lacking pleocytosis and Borrelia-specific antibodies in serum and cerebrospinal fluid. Results: Cerebrospinal fluid levels of B cell-associated markers (CXCL13, APRIL and BAFF) were significantly elevated in groups 1, 2 and 3 compared with the reference group, except for BAFF, which was not elevated in group 3. Regarding Th17-associated markers (IL-17A, CXCL1 and CCL20), CCL20 in cerebrospinal fluid was significantly elevated in groups 1, 2 and 3 compared with the reference group, while IL-17A and CXCL1 were elevated in group 1. Patients with time of recovery <3 months had lower cerebrospinal fluid levels of IL-17A, APRIL and BAFF compared to patients with recovery >3 months.
    [Show full text]
  • Cell TLR7 Activation and Plasmacytoid Dendritic CXCL13 Secretion in Human Monocytes Via HIV-1 Single-Stra
    HIV-1 Single-Stranded RNA Induces CXCL13 Secretion in Human Monocytes via TLR7 Activation and Plasmacytoid Dendritic Cell −Derived Type I IFN This information is current as of October 2, 2021. Kristen W. Cohen, Anne-Sophie Dugast, Galit Alter, M. Juliana McElrath and Leonidas Stamatatos J Immunol 2015; 194:2769-2775; Prepublished online 9 February 2015; doi: 10.4049/jimmunol.1400952 Downloaded from http://www.jimmunol.org/content/194/6/2769 References This article cites 49 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/194/6/2769.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 2, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology HIV-1 Single-Stranded RNA Induces CXCL13 Secretion in Human Monocytes via TLR7 Activation and Plasmacytoid Dendritic Cell–Derived Type I IFN Kristen W.
    [Show full text]
  • Chemokine CXCL13 Acts Via CXCR5-ERK Signaling In
    Shen et al. Journal of Neuroinflammation (2020) 17:335 https://doi.org/10.1186/s12974-020-02013-x RESEARCH Open Access Chemokine CXCL13 acts via CXCR5-ERK signaling in hippocampus to induce perioperative neurocognitive disorders in surgically treated mice Yanan Shen1, Yuan Zhang1, Lihai Chen1, Jiayue Du1, Hongguang Bao1, Yan Xing2, Mengmeng Cai1 and Yanna Si1* Abstract Background: Perioperative neurocognitive disorders (PNDs) occur frequently after surgery and worsen patient outcome. How C-X-C motif chemokine (CXCL) 13 and its sole receptor CXCR5 contribute to PNDs remains poorly understood. Methods: A PND model was created in adult male C57BL/6J and CXCR5−/− mice by exploratory laparotomy. Mice were pretreated via intracerebroventricular injection with recombinant CXCL13, short hairpin RNA against CXCL13 or a scrambled control RNA, or ERK inhibitor PD98059. Then surgery was performed to induce PNDs, and animals were assessed in the Barnes maze trial followed by a fear-conditioning test. Expression of CXCL13, CXCR5, and ERK in hippocampus was examined using Western blot, quantitative PCR, and immunohistochemistry. Levels of interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) in hippocampus were assessed by Western blot. Results: Surgery impaired learning and memory, and it increased expression of CXCL13 and CXCR5 in the hippocampus. CXCL13 knockdown partially reversed the effects of surgery on CXCR5 and cognitive dysfunction. CXCR5 knockout led to similar cognitive outcomes as CXCL13 knockdown, and it repressed surgery-induced activation of ERK and production of IL-1β and TNF-α in hippocampus. Recombinant CXCL13 induced cognitive deficits and increased the expression of phospho-ERK as well as IL-1β and TNF-α in hippocampus of wild-type mice, but not CXCR5−/− mice.
    [Show full text]
  • Downloaded from the TCGA Data Portal Expressed Genes (Degs) Between Primary Melanoma and (Https​://Tcga-Data.Nci.Nih.Gov/Tcga/) [10]
    Huang et al. Cancer Cell Int (2020) 20:195 https://doi.org/10.1186/s12935-020-01271-2 Cancer Cell International PRIMARY RESEARCH Open Access Identifcation of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients Biao Huang1,2,3† , Wei Han1,2,3†, Zu‑Feng Sheng1,2,3 and Guo‑Liang Shen1,2* Abstract Background: Skin cutaneous melanoma (SKCM) is one of the most malignant and aggressive cancers, causing about 72% of deaths in skin carcinoma. Although extensive study has explored the mechanism of recurrence and metasta‑ sis, the tumorigenesis of cutaneous melanoma remains unclear. Exploring the tumorigenesis mechanism may help identify prognostic biomarkers that could serve to guide cancer therapy. Method: Integrative bioinformatics analyses, including GEO database, TCGA database, DAVID, STRING, Metascape, GEPIA, cBioPortal, TRRUST, TIMER, TISIDB and DGIdb, were performed to unveil the hub genes participating in tumor progression and cancer‑associated immunology of SKCM. Furthermore, immunohistochemistry (IHC) staining was performed to validate diferential expression levels of hub genes between SKCM tissue and normal tissues from the First Afliated Hospital of Soochow University cohort. Results: A total of 308 diferentially expressed genes (DEGs) and 12 hub genes were found signifcantly diferentially expressed between SKCM and normal skin tissues. Functional annotation indicated that infammatory response, immune response was closely associated with SKCM tumorigenesis. KEGG pathways in hub genes include IL‑10 sign‑ aling and chemokine receptors bind chemokine signaling. Five chemokines members (CXCL9, CXCL10, CXCL13, CCL4, CCL5) were associated with better overall survival and pathological stages. IHC results suggested that signifcantly elevated CXCL9, CXCL10, CXCL13, CCL4 and CCL5 proteins expressed in the SKCM than in the normal tissues.
    [Show full text]
  • Cell Subsets NKT Βα Homing Patterns of Murine TCR Differential
    Differential Chemokine Responses and Homing Patterns of Murine TCR αβ NKT Cell Subsets This information is current as Brent Johnston, Chang H. Kim, Dulce Soler, Masashi Emoto of October 3, 2021. and Eugene C. Butcher J Immunol 2003; 171:2960-2969; ; doi: 10.4049/jimmunol.171.6.2960 http://www.jimmunol.org/content/171/6/2960 Downloaded from References This article cites 66 articles, 37 of which you can access for free at: http://www.jimmunol.org/content/171/6/2960.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 3, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Differential Chemokine Responses and Homing Patterns of Murine TCR␣␤ NKT Cell Subsets1 Brent Johnston,2* Chang H. Kim,3* Dulce Soler,† Masashi Emoto,‡ and Eugene C. Butcher* NKT cells play important roles in the regulation of diverse immune responses.
    [Show full text]
  • Baseline CXCL10 and CXCL13 Levels Are Predictive Biomarkers for Tumor Necrosis Factor Inhibitor Therapy in Patients with Moderat
    Han et al. Arthritis Research & Therapy (2016) 18:93 DOI 10.1186/s13075-016-0995-0 RESEARCH ARTICLE Open Access Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study Bobby Kwanghoon Han1*, Igor Kuzin2, John P. Gaughan3, Nancy J. Olsen4 and Andrea Bottaro2 Abstract Background: TNF inhibitors have been used as a treatment for moderate to severe RA patients. However, reliable biomarkers that predict therapeutic response to TNF inhibitors are lacking. In this study, we investigated whether chemokines may represent useful biomarkers to predict the response to TNF inhibitor therapy in RA. Methods: RA patients (n = 29) who were initiating adalimumab or etanercept were recruited from the rheumatology clinics at Cooper University Hospital. RA patients were evaluated at baseline and 14 weeks after TNF inhibitor therapy, and serum levels of CXCL10, CXCL13, and CCL20 were measured by ELISA. Responders (n = 16) were defined as patients who had good or moderate response at week 14 by EULAR response criteria, and nonresponders (n = 13) were defined as having no response. Results: Responders had higher levels of baseline CXCL10 and CXCL13 compared to nonresponders (p =0.03 and 0.002 respectively). There was no difference in CCL20 levels. CXCL10 and CXCL13 were highly correlated with each other, and were higher in seropositive RA patients. CXCL10 and CXCL13 levels were decreased after TNF inhibitor therapy in responders. Baseline additive levels of CXCL10 + 13 were correlated with changes in DAS score at 14 weeks after TNF inhibitor therapy (r = 0.42, p = 0.03), and ROC curve analyses for predictive ability of CXCL10 + 13 showed an AUC of 0.83.
    [Show full text]
  • CX3CL1 System in the Cross-Talk Between Chronic Lymphocytic Leukemia Cells and Tumor Microenvironment
    Leukemia (2011) 25, 1268–1277 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment E Ferretti1, M Bertolotto2, S Deaglio3, C Tripodo4, D Ribatti5, V Audrito3, F Blengio6, S Matis7, S Zupo8, D Rossi9, L Ottonello2, G Gaidano9, F Malavasi10, V Pistoia1,11 and A Corcione1,11 1Laboratory of Oncology, IRCCS G. Gaslini, Genova, Italy; 2Laboratory of Phagocyte Physiopathology and Inflammation, Department of Internal Medicine, University of Genova, Genova, Italy; 3Department of Genetics, Biology & Biochemistry, Human Genetics Foundation (HuGeF), University of Torino, Torino, Italy; 4Tumor Immunology Unit, Department of Health Science, Human Pathology Section, University of Palermo, Palermo, Italy; 5Department of Human Anatomy and Histology, University of Bari, Bari, Italy; 6Laboratory of Molecular Biology, Gaslini Institute, Genova, Italy; 7Medical Oncology C, National Cancer Research Institute, Genova, Italy; 8Laboratory of Diagnostics of Lymphoproliferative Disorders, National Cancer Research Institute, Genova, Italy; 9Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro, University of Eastern Piedmont, Novara, Italy and 10Department of Genetics, Biology & Biochemistry, Research Center for Experimental Medicine (CeRMS), University of Torino, Torino, Italy Several chemokines/chemokine receptors such as CCR7, Additional prognostic markers are surface CD38 and intra- CXCR4 and CXCR5 attract chronic lymphocytic leukemia cellular ZAP-70 whose expression in leukemic cells correlates (CLL) cells to specific microenvironments. Here we have with unfavorable clinical outcome.2,4,5 Finally, different chro- investigated whether the CX3CR1/CX3CL1 axis is involved in the interaction of CLL with their microenvironment.
    [Show full text]